Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response  by Badillo, Andrea T. et al.
M
a
I
c
t
a
a
T
b
g
w
t
Biology of Blood and Marrow Transplantation 13:412-422 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1304-0001$32.00/0
doi:10.1016/j.bbmt.2006.12.447
4urine Bone Marrow Stromal Progenitor Cells Elicit
n In Vivo Cellular and Humoral Alloimmune Response
Andrea T. Badillo, Kirstin J. Beggs, Elisabeth H. Javazon, Jessica C. Tebbets, and Alan W. Flake
The Center for Fetal Research, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
The ﬁrst two authors contributed equally to this work.
This work was supported by grants R01 HL73253-01 from the National Institutes of Health (to A.W.F.). A.W.F. is
also supported by funds from Ruth and Tristram C. Colket, Jr., Chair of Pediatric Surgery.
Correspondence and reprint requests: Alan W. Flake, MD, Department of Surgery, Abramson Research Center,
The Children’s Institute for Surgical Science, 3615 Civic Center Boulevard, Room 1116B, Philadelphia, PA
19104-4318 (e-mail: ﬂake@email.chop.edu).
Received June 27, 2006; accepted December 21, 2006
ABSTRACT
Stromal progenitor cells (SPC) exhibit immunosuppressive effects in vitro that have led to speculation
regarding their capacity to evade host immune recognition and to treat autoimmune diseases and gravt-versus-
host disease. However, there is little in vivo experimental data to support these immunologic claims. To assess
immune recognition of SPC in vivo, we evaluated the immune response of animals transplanted with SPC.
C57BL/6 (B6) or Balb/c adult, murine, bone marrow-derived SPC (AmSPC) were administered by intraperi-
toneal injection into B6 recipients. T cell proliferation and alloantibody response was assessed from spleens
and peripheral blood harvested from transplanted animals and analyzed by cell proliferation assay and flow
cytometry. To assess tolerance induction, transplanted animals also received allogeneic skin grafts. Animals
injected with allogeneic AmSPC mounted an accelerated CD4 response to alloantigen compared to syngeneic
AmSPC injected and uninjected controls. Allogeneic AmSPC-injected animals also demonstrated high titers
(>1:1000) of antibody directed against allogeneic AmSPC targets. Animals primed with donor or host-matched
AmSPC also failed to induce tolerance, and all animals exhibited rejection of allogeneic skin grafts (n  7, P <
.0001). In contrast to their in vitro behavior, our data demonstrate that AmSPC are recognized by the host
immune system in vivo, elicit a cellular and humoral immune response, and fail to induce tolerance. These
findings have significant implications for all allogeneic SPC-based therapeutic strategies.
© 2007 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Mesenchymal “stem” cells (MSC) are multipotent
ells derived from bone marrow and a variety of other
issues [1,2]. Although the term MSC is widely used,
ll populations described thus far are heterogeneous
nd contain cells with a hierarchy of potentiality.
hey are, therefore, more appropriately referred to as
one marrow (or other tissue derived) stromal pro-
enitor cells (SPC), which is the terminology that we
ill use throughout this report. They are of potential
herapeutic value because of their extensive capacity e
12or in vitro expansion, their capacity for induced dif-
erentiation into at least some mesenchymal lineages,
nd their relative ease of genetic manipulation [3]. In
ddition, SPC have interesting immunologic proper-
ies in vitro, which have led to speculation and con-
roversy regarding their in vivo immunologic behav-
or. Although the mechanisms are not fully deﬁned,
PC have been demonstrated in vitro by multiple
nvestigators to suppress stimulated T cells in cocul-
ure experiments [4-19]. Because of these in vitro
bservations, it has been suggested that SPC may
vade alloimmune surveillance, induce speciﬁc immu-
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Immune Recognition of Stromal Progenitor Cells In Vivo 413ologic tolerance, and suppress graft-versus-host-dis-
ase (GVHD) [20-28], but there is little clinical or
xperimental data to support these claims. In fact, a
ecent study demonstrated the in vivo elimination of
ubcutaneously implanted, gene-modiﬁed, allogeneic
PC in a murine system [29]. The immune rejection
f allogeneic SPC would complicate their use in ther-
peutic applications requiring the long-term persis-
ence of allogeneic cells for sustained clinical beneﬁt.
In this study we utilize a well-characterized pop-
lation of murine adult bone marrow-derived stromal
rogenitor cells (AmSPC), that are devoid of hemato-
oietic cells, and satisfy deﬁning criteria that are
idely used for so-called MSC, to characterize the
lloresponse to SPC after intraperitoneal administra-
ion. In contrast to their in vitro behavior, our data
emonstrate that SPC are recognized by the host
mmune system in vivo, and elicit both host cellular
nd antibody immune responses. To test the immu-
omodulatory capacity of AmSPC in vivo, we also
erformed allogeneic skin grafting and demonstrate
kin graft rejection in animals instead of tolerance
nduction. These ﬁndings have signiﬁcant implica-
ions for all allogeneic SPC-based therapeutic strate-
ies.
ATERIALS AND METHODS
mSPC Isolation and Expansion
Femurs and tibias were removed from euthanized
-12-week-old C57BL/6 (B6) and Balb/c male mice
obtained from Jackson Laboratories, Bar Harbor,
E). The bone marrow was ﬂushed via a 23-gauge
eedle with complete MesenCult Basal Medium for
urine Mesenchymal Stem Cells (StemCell Technol-
gies, Vancouver, Canada) containing mesenchymal
tem cell stimulatory supplements, 100 U/mL peni-
illin, and 100 g/mL streptomycin (Life Technolo-
ies/Invitrogen, Carlsbad, CA). Bone marrow from
ach mouse was ﬁltered through a 70-m nylon ﬁlter.
ed cell lysis was performed by the addition of am-
onium chloride (StemCell Technologies). Cells
ere plated into 6-well tissue culture plates (Falcon,
ranklin Lakes, NJ), and kept in a humidiﬁed incuba-
or at 37°C and 5% CO2. Adherent cells were lifted
nce 90% conﬂuent using 0.25% Trypsin 0.05 mM
DTA (Life Technologies/Invitrogen) and expanded
y replating at 5000 cells/cm2. Complete MesenCult
edia was used to feed expanding cells every 3 to 4
ays.
low Cytometric Analysis of Immune Phenotype
Both untreated AmSPCs and AmSPCs treated
ith interferon gamma (IFN-; 200 ng/mL for 72 h)
ere suspended in 100 L of PBS and incubated in FC
locking antibody (CD16/CD32) (BD Biosciences sharmingen, San Diego, CA) for 10 min at room
emperature. AmSPCs were incubated with primary
ntibody directly conjugated to phycoerythrin (PE) (1
g/L  106 cells) for 30 min at 4°C, washed twice
ith PBS, and stained with 1 g/ml propidium iodine
rior to analysis. Primary antibodies with speciﬁcity
or the surface antigens CD3, CD11b, CD13, CD31,
D44, CD45, CD90, C-kit (CD117), major histo-
ompatibility complex (MHC) I, MHC II, and Sca-1
ere used (BD Pharmingen).
rimary Mixed Lymphocyte Cultures in the
resence of AmSPC
B6 responder-matched AmSPC were trypsinized
t passage 13 (p.13). Cells were counted by trypan
lue exclusion (95% viable). AmSPC were plated at
000 cells/cm2 into 12-well tissue culture-treated
lates (Falcon). AmSPC were incubated alone over-
ight in complete Mesencult media to allow adher-
nce to the dish. Spleens were harvested from 12-
eek-old female B6 mice as responder cells, and from
2-week-old Balb/c mice as stimulator cells. Spleens
ere processed using 70-m cell strainers and 5-mL
yringes (BD Biosciences) to achieve a single cell sus-
ension. Once a single cell suspension was prepared,
ed blood cells were lysed using Ammonium Chloride
StemCell Technologies). Responder cells were
tained with CFDA SE tracking dye (carboxyﬂuores-
ein diacetate succinimidyl ester [CFSE]; Molecular
robes, Eugene, OR) using the manufacturers instruc-
ions. Stimulator splenocytes were given 2500 cGy
rradiation in a Cs135 gamma irradiator. After stain-
ng was complete, cells were washed 3 times in com-
lete assay medium, Iscove’s Modiﬁed Dulbecco me-
ia, with nonessential amino acids, sodium pyruvate,
00 U penicillin, 100 mg streptomycin, 55 mM Beta-
ercaptoethanol (all from Life Technologies/Invitro-
en), and 10% fetal bovine serum (FBS) (HyClone,
ogan, UT). Media was removed from the 24-h ad-
erent AmSPC cultures and responder, and stimulator
plenocytes were added to appropriate wells at the
oncentration of 1.2  106 cells/cm2 and 6  105
ells/cm2 (responder:stimulator ratio of 2:1). Alterna-
ively, the polyclonal lymphocyte stimulant phytohe-
agluttinin (PHA) (Sigma-Aldrich, St. Louis, MO)
as added to stimulate cultures at a ﬁnal concentra-
ion of 10 mg/ml. All experiments were performed a
inimum of 3 times, and all samples prepared in
riplicate. Optimal culture conditions and time peri-
ds required for peak proliferation in PHA and alloan-
igen stimulated cultures were determined from pilot
tudies. Proliferation was observed at 3 days in mito-
en stimulated cultures with no proliferation observed
n alloantigen stimulated cultures until 7 days in cul-
ure. As a result, PHA stimulated cultures were incu-
ated at 37°C, 5% CO2 for 3 days and alloantigen
timulated cultures were incubated for 7 days under
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A. T. Badillo et al.414he same conditions. The above experiments were also
erformed with stimulator matched Balb/c AmSPC
nd repeated in a transwell assay system. For transwell
ssays, either B6 or Balb/c AmSPC were plated in the
ower chamber and separated from splenocytes in the
pper chamber by a 4-m pore size semipermeable
embrane insert.
mSPC Preparation for Injections
Animals were housed in the Laboratory Animal
acility of the Abramson Research Center at the Chil-
ren’s Hospital of Philadelphia. The experimental
rotocols were approved by the Institutional Animal
are and Use Committee following guidelines set
orth in the National Institutes of Health Guide for
he Care and Use of Laboratory Animals. AmSPC
ere trypsinized at passage 13 and a single cell sus-
ension created. Cells were washed 3 times with 1
PBS (Life Technologies/Invitrogen). Cells were
ounted by trypan blue exclusion (95% viable). Cells
ere resuspended at 5  106 cells/mL in 1 dPBS
ith 1% normal mouse serum. A volume of 200 L of
he cell suspension was immediately injected into the
eritoneal cavity of 6-8-week-old female B6 mice.
his injection was considered the zero-week time
oint. A second injection prepared exactly as described
bove was administered at the 4-week time point.
nalysis of T Cell Proliferation in Response
o Alloantigen
Spleens were removed from treated B6 mice 2
eeks after the second immunization (6 week time
oint) and Balb/c spleens were harvested as stimulator
ells. To increase the sensitivity of detection for
iscrete proliferation peaks, the CD4 lymphocyte
raction of responder splenocytes cell populations
as selected using a CD4 T cell isolation kit and
n autoMACS cell separator according to the man-
facturer’s instructions (Miltenyi BioTech, Auburn,
A). CD4 cells were stained with CFSE and stimu-
ator cells treated with irradiation as previously de-
cribed. Control CD4 cells were obtained from age-
atched animals for comparison. All samples were
repared in triplicate. Responder and stimulator cells
ere added to appropriate wells at the concentration
f 1.2106 cells/cm2 and6105 cells/cm2 (responder:
timulator ratio of 2:1) in complete assay medium.
uriﬁed anti CD3 antibody (BD Pharmingen) was
dded to the control wells at a ﬁnal concentration of 1
g/L. Cultures were incubated at 37°C, 5% CO2
nd analyzed at 3.5 and 5.5 daytime points. Three
amples per group were analyzed by ﬂow cytometry
ith a FACS Calibur system and Cell Quest Pro
oftware. alloantibody Analysis
Mice were bled from the retro-orbital vein at 0, 2,
, 5, and 6 weeks. Blood was placed in a clot activating
ube and centrifuged for 10 min at 500 g. Serum was
spirated and frozen at 80°C. Target B6 (H2b) and
alb/c (H2d) p13 AmSPC were treated with IFN-
200 ng/mL) for 72 h prior to coincubation. Cells
ere counted by trypan blue exclusion (95% viable
or both IFN--treated and untreated target AmSPC).
reated and untreated target AmSPC were coincu-
ated for 1 h with dilutions of serum from injected
nimals (1:10, 1:100, 1:1000) in FACS staining buffer,
1 dPBS (Life Technologies/Invitrogen), 0.5% BSA
Sigma-Aldrich), and 0.1% Sodium Azide (Sigma-Al-
rich)]. Cells were washed with FACS staining buffer
nd then incubated with anti-Mouse IgG (FITC con-
ugated) and IgM (PE conjugated) antibodies (Jackson
mmunoResearch Inc., West Grove, PA) for 30 min.
dditional experiments using p13 CBA (H2k) AmSPC
argets with allogeneic primed animal sera were also
erformed. Cells were washed using FACS staining
uffer. Three cell samples for each condition were
hen analyzed by dual color ﬂow cytometry.
kin Grafting
Six- to 8-week-old, female B6 mice received
ntraperitoneal injections with either syngeneic (B6)
mSPC, allogeneic (Balb/c) AmSPC, syngeneic (B6)
plenocytes, or allogeneic (Balb/c) splenocytes at the
- and 4-week time points as described above. At 6
eeks, 2 weeks after the second injection, skin grafting
as performed by a modiﬁcation of the technique
escribed by Billingham and Medawar [30]. Brieﬂy,
ull thickness donor skin grafts (1.5  0.5 cm2) were
repared from the ventral skin of Balb/c mice and
ransferred to recipient sites on B6 mice. Recipient
ites were created on the lateral thorax of both
mSPC or splenocyte injected and noninjected con-
rol mice while carefully preserving the panniculus
arnosus. Autografting was performed using skin re-
oved from the allograft site to serve as a technical
ontrol. Each mouse received an autograft and allo-
raft. The grafts were covered with petroleum gauze
nd held in place with a Band Aid to create a pressure
ressing. Dressings were removed after 5 days. Non-
dherent grafts were considered technical failures and
ere excluded. Adherent grafts were monitored for
igns of rejection (hardening of the graft, and necrosis)
nd photographs were taken daily. Grafts were con-
idered rejected when 90% of the surface area was
ecrotic and the graft hardened. Photographs of the
rafts were also reviewed in series at the end of the
xperiment by an investigator blinded to the group
nd treatment.
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Immune Recognition of Stromal Progenitor Cells In Vivo 415tatistical Analysis
Data are presented as the mean SD. Means were
ompared by Student’s t-test. Kaplan-Meier survival
urves were created to compare skin graft rejection.
ifferences between groups were determined by log
ank analysis. Probability values of P  .05 were in-
erpreted as statistically signiﬁcant.
ESULTS
haracteristics of AmSPC
AmSPC isolated by the described methodology are
orphologically similar to human and rat “MSC,” con-
ain a high percentage of CFU-f after passaging (up to
0%), and demonstrate linear expansion for more
han 100 population doublings. Osteogenic, adipo-
enic, and chondrogenic differentiation can be in-
uced by deﬁned culture conditions. Phenotypically,
mSPC are Sca-1, VCAM-1, CD44, CD31,
D45, and CD90. The cells display the following
mmune phenotype, MHC Class I, MHC II,
D40, CD80/, CD86. Upon treatment with in-
erferon- upregulation of MHC I is observed, MHC
I expression is induced, and costimulatory expression
emains unchanged (Figure 1).
n Vitro Suppression of T Cell Proliferation
In the presence of AmSPC, B6 responder spleno-
yte proliferation was inhibited in MLR cultures. This
uppression was observed for both CD4 and CD8
cells in response to both alloantigen (Balb/c spleno-
igure 1. Immune phenotype of AmSPC  IFN-. AmSPC expre
olecules CD40, CD80, and CD86. With IFN- pretreatment (
xpression is induced, but costimulatory marker expression remains unchaytes) and polyclonal mitogen stimulation in vitro
Figure 2A). This suppression occurred in the pres-
nce of both responder- matched B6 AmSPC and
timulator-matched Balb/c AmSPC, and was there-
ore independent of MHC matching between re-
ponder and AmSPC cell populations. Furthermore,
he suppression was contact dependent with no sup-
ression observed in a transwell system (Figure 2B).
n Vivo Cellular and Humoral Response to
mSPC Alloantigen
To examine the in vivo host cellular response to
njected AmSPC, spleens from B6 animals injected
ith either B6 or Balb/c AmSPC were harvested for T
ell proliferation assays in response to alloantigen
Balb/c splenocytes). Nine of 10 animals injected with
alb/c (allogeneic) AmSPC mounted an accelerated
D4 T cell proliferation response (as indicated by
ecreases in the ﬂuorescence intensity shifting histo-
ram peaks to the left) compared to animals injected
ith syngeneic AmSPC or uninjected controls at 3.5
ays after restimulation with alloantigen (Figure 3A).
t 5.5 days after alloantigen stimulation, all animals
njected with B6 (syngeneic) AmSPC demonstrated
nitiation of T cell proliferation. Allogeneic-primed
ells exhibited continued proliferation, with the ma-
ority of cells having shifted to the left and represented
s a single heterogenous peak of cell divisions (Figure
B). No such increase in T cell proliferation was
bserved in uninjected animals. At the 7-day time
oint, all uninjected control CD4 cell populations
I constitutively but do not express MHC II or the costimulatory
/mL for 72 h), MHC I expression is upregulated and MHC IIss MHC
200 ngnged.
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A. T. Badillo et al.416xhibited proliferation compared to unstimulated con-
rol cultures (data not shown).
Mice primed with allogeneic AmSPC demon-
trated both primary and secondary alloantibody re-
ponses, as indicated by the presence of both IgM and
gG antibody isotypes. Extremely high IgG alloanti-
ody titers (1:1000) were found in all 5 of the ani-
als injected with allogeneic AmSPC (Figure 4a).
lloantibody binding was increased in samples where
mSPC were treated with interferon-. Low IgG
iters (1:100) were generated in animals injected
ith syngeneic AmSPC (Figure 4b). Sera from allo-
eneic AmSPC primed animals was also incubated
ith third party CBA (H2k) AmSPC. Compared to
gG titers detected with Balb/c targets, lower IgG
igure 2. AmSPC inhibition of T cell proliferation. Representa
ymphocyte cultures. The presence of B6 responder-matched or B
D4 and CD8 proliferation in both mitogen and alloantigen (B
lower chamber) from splenocytes (upper chamber) does not result in
ivision halves the ﬂuorescence intensity moving the population to t
D8 fraction of PHA stimulated culture, 3 	 CD4 fraction of al
ulture.)iters were seen against CBA targets (n 	 5, Figure 5). tkin Graft Rejection with Alloantigen Priming
B6 mice primed with an intraperitoneal injection
f Balb/c, allogeneic AmSPC (n 	 7) rejected Balb/c
llogeneic skin grafts with a mean time to rejection of
.71  0.39 days compared to 8.375  0.07 days for
oninjected controls (n 	 12, P  .0001). B6 animals
njected with B6, syngeneic AmSPC rejected Balb/c,
llogeneic skin grafts at a mean of 7.5  0.2 days (n 	
0; P  .0001 compared individually to both alloge-
eic AmSPC-injected and noninjected controls). Skin
raft rejection of AmSPC-primed B6 animals was also
ompared to B6 animals primed with Balb/c, alloge-
eic, or B6, syngeneic splenocytes. Kaplan-Meier
nalysis of graft survival did not demonstrate a statis-
stogram demonstrating direct coculture of AmSPC with mixed
timulator-matched AmSPC results in inhibition of B6 responder
lenocyte) stimulated cultures (A). Transwell separation of AmSPC
inhibition (B). Response is measured by CFDA-SE divisions—each
n the histogram. (1	 CD4 fraction of PHA stimulated cells, 2	
en stimulated culture, 4 	 CD8 fraction of alloantigen stimulatedtive hi
alb/c s
alb/c sp
T cell
he left o
loantigically signiﬁcant difference between AmSPC-primed
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Immune Recognition of Stromal Progenitor Cells In Vivo 417nimals and their splenocyte counterparts. Balb/c al-
ogeneic-primed animals exhibited statistically signif-
cant acceleration in graft rejection compared to B6
yngeneic-injected and uninjected control animals
P  .05; Figure 6). Autografts were not rejected. The
echnical success rate for all skin grafting was 97%.
ISCUSSION
In agreement with previous studies of “MSC” im-
une function in vitro, AmSPC clearly inhibit T cell
roliferative responses to allogeneic stimulation in
oculture experiments. The multitude of studies
emonstrating such in vitro suppression has formed
he basis of claims that MSC are similarly immuno-
uppressive and poorly immunogenic in vivo. Our
ata, however, demonstrates that the introduction
f allogeneic AmSPC into an immunologically com-
etent animal elicits both a cellular and humoral host
mmune response. Sensitization of host CD4 lym-
hocytes is evidenced both by the increased prolifer-
tion of T cells observed upon restimulation with
lloantigen and the detection of high titer alloanti-
ody after immunization with allogeneic AmSPC.
urthermore, injection of donor-matched AmSPC fail
o induce host tolerance to allogeneic skin grafting.
The mechanism of SPC mediated in vitro sup-
ression of T cell proliferation remains to be fully
eﬁned. There is agreement that suppression of T cell
roliferation after stimulation by polyclonal mitogens,
nti CD3 antibody, or alloantigen appears to be inde-
endent of MHC matching between the SPC and the
igure 3. Six-week posttreatment T cell response after 7-day incu
nimals injected with either Balb/c (allogeneic) AmSPC, B6 (syngen
ith CFSE, and T cell proliferation in response to stimulation
uorescence intensity and histogram peak shifts to the left. (A) Afte
nitiate T cell proliferation, whereas syngeneic primed (blue line) an
n coculture, more than half of allogeneic-primed cells (green line)
eterogenous number of cell divisions. In comparison, syngeneic-p
n coculture, all responder populations demonstrate a proliferativecells [8,10,12]. There have been conﬂicting reports rn whether suppression is mediated by a soluble factor
n supernatants or whether cell-cell contact is required
5,7-10,17]. In our own study, the inhibition of T cell
roliferation was contact dependent. This implies that
hese effects on lymphocyte function in vitro are me-
iated by different mechanisms. A variety of molecular
echanisms have been proposed to explain MSC-
ediated in vitro suppression including IDO type
eactions [16], veto-like activity [31], induction of T
ell anergy [19], inhibition of cytotoxic lymphocytes
4,5,17], and NK cells [13] in mixed lymphocyte cul-
ure, alteration of antigen presenting cell function
4,7,9], and production of T cells with regulatory or
uppressive phenotypes [4,13]. Failure to arrive at a
onsensus regarding the precise mechanisms respon-
ible for these in vitro observations may partly result
rom study differences in the cell population or type of
timulation used in coculture experiments [18].
Suppressive culture conditions are associated with
xtremely high cell densities and local concentrations
f suppressive cytokines relative to physiologic condi-
ions. In contrast, systemic administration of SPC
ould generally result in exposure of host immune
ells to SPC at a much lower frequency. Thus, the
ikelihood of formation of the cell-cell networks and
ocal cytokine milieus that occur in vitro would be
inimal. In this context, it is likely that in vivo pre-
entation of SPC may have entirely different immune
onsequences than those anticipated from in vitro
tudies such as the alloimmunization observed in this
tudy.
One other group has shown the in vivo immune
with alloantigen. CD4 T cells were isolated from spleens of B6
SPC, or uninjected animals. B6 CD4 responder cells were stained
lloantigen (Balb/c splenocytes) is indicated by decreases in the
ays of alloantigen stimulation, alloantigen-primed cells (green line)
jected cells (pink line) have not begun to divide. (B) After 5.5 days
roliferated and are represented as a single left peak comprised of a
ells (blue line) have just begun to proliferate. At the end of 7 days
se compared to unstimulated controls (purple ﬁlled curve).bation
eic) Am
with a
r 3.5 d
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have p
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A. T. Badillo et al.418ontrolled study [29]. Using murine SPC engineered
o release erythropoietin, they demonstrate high re-
ipient plasma levels of antibody to erythropoietin and
ecreasing host hematocrit with repeat challenges of
ubcutaneously implanted allogeneic SPC. Histologic
nalysis of the subcutaneous implants for CD4 and
D8 cells yields indirect evidence of in vivo host
ellular immune response. In our study, we utilized a
ontransduced cell population of similar immune phe-
otype and passage and demonstrate evidence of a
umoral response directed at SPC antigens rather
han at a transgene product. Furthermore, host cellu-
ar recognition of AmSPC antigens is indicated by the
ccelerated proliferative response of CD4 lympho-
ytes from 6-week posttreatment B6 animals upon
estimulation with Balb/c, allogeneic stimulator
plenocytes, and suggests the induction of a memory
cell response following initial antigen presentation in
ivo. In comparison to animals injected with AmSPC,
igure 4. Alloantibody response of animals transplanted with Am
mSPC were incubated with varying dilutions of mouse serum from
nd B6 (syngeneic) AmSPC (b). IgG and IgM antibody binding was
n animals injected with Balb/c (allogeneic) AmSPC compared to lnimals initially injected with allogeneic splenocytes rhowed both increased magnitude and kinetics in their
esponse (data not shown). This is most likely because
f a potent response against MHC Class II, which is
xpressed on the majority of splenocytes and is only
nducible on AmSPC.
In addition to eliciting host immune responses,
mSPC also fail to prevent skin graft rejection. In
ontrast to other studies demonstrating skin graft pro-
ongation [6,32], our results demonstrate that animals
njected with allogeneic AmSPC reject allogeneic skin
rafts with the same kinetics as animals injected with
llogeneic splenocytes. In the above-mentioned stud-
es skin graft prolongation is between 1 and 4 days,
nd although statistically signiﬁcant, such prologation
s unlikely to be of clinical or therapeutic signiﬁcance.
n our study, animals primed with allogeneic AmSPC
xhibited a statistically signiﬁcant acceleration in the
ime to skin graft rejection compared to syngeneic
mSPC controls. Although the window of skin graft
ntreated target Balb/c AmSPC and IFN--treated Balb/c target
4, 5, and 6 weeks postpriming with Balb/c (allogeneic) AmSPC (a)
ed by ﬂow cytometric analysis. High alloantibody titers were found
rs exhibited in animals treated with B6 (syngeneic) AmSPC.SPC. U
0, 2,
measurejection between the groups in this study is narrow,
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llogeneic AmSPC are not tolerogenic.
The rejection of allogeneic skin grafts seen in
rimed animals in our study also provides indirect
vidence of the generation of T cell responses to
llogeneic AmSPC. Acute graft rejection is a T cell-
ediated immune response. In all likelihood, host T
ells, sensitized to donor alloantigen by intraperito-
eal SPC injections, recognize alloantigen within the
raft and generate cytotoxic responses resulting in
igure 5. Antibody binding to third-party AmSPC targets. (A) IgG
iters detected from serum of animals primed with Balb/c (alloge-
eic) AmSPC at 6 weeks posttreatment and incubated with Balb/c
mSPC targets. (B) IgG titers detected using serum from the same
nimals incubated with CBA (third-party) AmSPC targets. Green
ine 	 1:10 dilution, pink line 	 1:100 dilution, blue line 	 1:1000
ilution.
igure 6. Kaplan-Meier analysis of skin graft survival. B6 mice tre
arlier rejection of Balb/c skin grafts compared to animals treated w
P  .05).cute graft rejection. Animals primed with syngeneic
PC exhibited a mean graft rejection time intermedi-
te to that of allogeneic injection recipients and un-
njected controls but no difference in graft survival
urve compared to uninjected controls. We attribute
he faster mean graft rejection time of syngeneic in-
ection recipients to an enhanced nonspeciﬁc inﬂam-
atory state produced by intraperitoneal injections
nd the presence of foreign material within the peri-
oneal cavity. Peritoneal macrophages and resident
K cells phagocytose foreign material as part of the
nnate immune response. Once activated, macro-
hages produce a variety of cytokines that inﬂuence
ymphocyte effector functions and the adaptive im-
une response [33]. In this fashion, the introduction
f cellular material can serve as an adjuvant thereby
nhancing the rejection of allogeneic skin grafts in
nimals primed with syngeneic AmSPC. Accelerated
kin graft rejection argues against the capacity of SPC
o escape immune surveillance or to be tolerogenic in
mmune competent animals.
Additionally, alloantibody is produced in high ti-
ers against allogeneic AmSPC. Binding of alloanti-
ody is increased with interferon- treatment, sug-
esting that upregulation of class I contributes to this
henomena. The higher antibody titers detected when
llogeneic primed animal serum was incubated with
llogeneic AmSPC compared to third-party AmSPC
argets also suggests that the alloantibody response is
HC mediated. An interesting point to further inves-
igate would be to determine if there is antibody
ith Balb/c (allogeneic) AmSPC or allogeneic splenocytes exhibited
(syngeneic) AmSPC, syngeneic splenocytes, or untreated controlsated w
ith B6
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A. T. Badillo et al.420enerated against MHC Class II. A recent study ex-
mining host immune responses to multipotent adult
rogenitor cells (MAPC), a cell type with a similar
HC class I and II antigen expression proﬁle to SPC,
howed indirect evidence of upregulation of MHC
lass II antigen expression in vivo contributing to
APC immune clearance [34]. Given that an area of
njection would be prone to inﬂammation, and inter-
eron- would be produced, upregulation of Class I
nd Class II expression is very likely.
Lower levels of antibody activity were observed in
nimals injected with syngeneic AmSPC. We inter-
ret this as a low-level immune response to FBS an-
igens presented by the AmSPC. AmSPC are sub-
ected to long-term culture in FBS. During this time
he cells incorporate many xenoproteins that can be
xpressed on their MHC. It has been well docu-
ented that FBS sensitization occurs when cultured
ells are transplanted into immunocompetent animals
35-37]. As FBS-derived proteins should be presented
qually by allogeneic, syngeneic, or third-party cells,
he greater magnitude of humoral and cellular im-
une response observed with allogeneic cells can only
e explained by response to alloantigen.
Because species-related differences in SPC have
een well documented, it is important to note that we
ave conﬁrmed that the murine SPC utilized in this
tudy have similar in vitro suppressive properties to
hose described for the human and rat cells used in
revious immunologic studies of so-called MSCs.
peciﬁcally, AmSPC suppress T cell proliferation in
itro to polyclonal mitogen and allogeneic stimulation
n a non-MHC restricted manner. In agreement with
any studies, our cells require cell-cell contact for
uppression to occur. Thus, the results of this study
ould seem relevant to the clinical application of
uman SPC, and would suggest that clinical systemic
dministration of allogeneic SPC in the absence of
mmunosuppression would elicit an alloimmune re-
ponse.
Perhaps the strongest evidence for the immuno-
enicity of SPC is provided by the disconnect between
n vitro studies and supporting in vivo data. Despite
he large number of studies supporting the immune
uppressive capacity of SPC in vitro, there is a paucity
f in vivo data in the immunologically competent host
hat supports the capacity of allogeneic or xenogeneic
PC to evade the immune response or induce toler-
nce to donor antigen. The vast majority of studies
ocumenting in vivo persistence of allogeneic or xe-
ogeneic SPC were performed in either immunode-
cient or irradiated hosts, or were site directed into
mmune privileged sites such as the brain [38-43]. The
ew studies demonstrating long-term engraftment of
llogeneic SPC have been methodologically ﬂawed,
ither by utilization of a hematopoietically contami-
ated cell population [44,45] or by the use of nonrig-rous detection methodology such as membrane as-
ociated dyes [28,46,47] as the sole evidence of donor
ell persistence. The issue is also complicated by the
ttribution of beneﬁcial physiologic effect to assumed
ngraftment and differentiation of SPC. There are
ow many documented instances of beneﬁcial effect
ia paracrine mechanisms [48-50] that can transiently
e provided by allogeneic cells. If, in fact, SPC were
mmune privileged cells that could escape immune
urveillance, one would anticipate that after years of
ffort by many laboratories, a large number of studies
learly documenting engraftment and persistence of
llogeneic SPC in immunocompetent hosts would be
vailable.
Finally, the results of this study should be inter-
reted in appropriate context. Our results clearly
emonstrate that allogeneic AmSPC delivered by in-
raperitoneal injection elicit a primary and secondary
lloimmune response. This argues against the capacity
f SPC to avoid immune surveillance or, at least in this
etting, to be tolerogenic. Furthermore, this immune
esponse induces cytotoxic effector functions resulting
n donor skin graft rejection. Although the speciﬁc
limination of donor SPC has not been clearly dem-
nstrated, prevailing evidence would suggest SPC to
e cleared by these same mechanisms. It is possible,
owever, that SPC are able to set up local immune
uppressive environments after immune recognition
llowing their persistence in host tissues. It is also
ossible that in studies in which microchimerism (pcr
etectable chimerism) persists, the frequency of donor
ells is below the threshold of immune activation.
lariﬁcation of these issues is important prior to clin-
cal applications utilizing allogeneic SPC. At the very
east, our data suggests that in vitro immune properties
f SPC cannot be extrapolated into assertions that SPC
re immunosuppressive, immunomodulatory, or tolero-
enic in vivo. Such assertions should only be based on
urther experimental evidence from in vivo studies.
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